Jiaxing University Master Degree Cultivation Base, Zhejiang Chinese Medical University, Jiaxing, Zhejiang, China.
Department of Ultrasound Intervention, The Third Affiliated Hospital of Jiaxing University, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, China.
Med Sci Monit. 2024 Nov 1;30:e945874. doi: 10.12659/MSM.945874.
BACKGROUND Lumbodorsal fasciitis (LF) is a condition in which muscle and fascial lesions cause low back pain (LBP) and limited mobility. This retrospective study aimed to explore the efficacy and safety of ultrasound-guided fascial hydrodissection combined with eperisone for treating LF. MATERIAL AND METHODS A total of 103 patients with LF were selected and divided into a combined therapy (CT) group (ultrasound-guided fascial hydrodissection and oral drugs of eperisone) and single medication (SM) group (oral drugs of celecoxib and eperisone). Outcomes were evaluated using the visual analog scale (VAS) and Oswestry disability index (ODI) at baseline and at 2 weeks, 1 month, and 3 months after treatment. The adverse reactions and complications of the 2 groups were recorded. RESULTS There were no significant differences in the baseline characteristics of the 2 groups (P>0.05). After treatment, all scores showed a statistically significant improvement at 2 weeks and 1 month (P<0.05). The VAS and ODI scores showed a significant effect by time and group (P<0.001). The results also showed significant group-by-time interactions (P<0.001). Patients in the CT group had lower scores at any follow-up time (P<0.05). At 3 months, the scores slightly increased. There were no adverse reactions or complications in the CT group; however, the SM group had 4 cases of gastrointestinal reactions. CONCLUSIONS Ultrasound-guided fascial hydrodissection combined with eperisone therapy can effectively relieve LBP and improve lumbar function in treating LF. Moreover, this procedure is considered safe.
腰背筋膜筋膜炎（LF）是一种肌肉和筋膜病变导致下腰痛（LBP）和活动受限的疾病。本回顾性研究旨在探讨超声引导下筋膜松解术联合乙哌立松治疗 LF 的疗效和安全性。
共选择 103 例 LF 患者，分为联合治疗（CT）组（超声引导下筋膜松解术和口服乙哌立松药物）和单一药物（SM）组（口服塞来昔布和乙哌立松药物）。在治疗前、治疗后 2 周、1 个月和 3 个月，采用视觉模拟评分（VAS）和 Oswestry 残疾指数（ODI）评估疗效。记录两组的不良反应和并发症。
两组患者的基线特征无统计学差异（P>0.05）。治疗后，两组 VAS 和 ODI 评分在 2 周和 1 个月时均有统计学意义（P<0.05）。VAS 和 ODI 评分均显示时间和组间有显著交互作用（P<0.001）。任何随访时间点，CT 组的评分均较低（P<0.05）。3 个月时，评分略有增加。CT 组无不良反应或并发症；SM 组有 4 例胃肠道反应。
超声引导下筋膜松解术联合乙哌立松治疗可有效缓解 LF 患者的 LBP，改善腰椎功能，且该操作安全。
